🟠 Conclusions: Sanofi faces significant challenges in addressing #FDA concerns over manufacturing compliance. 
Swift resolution is crucial to restoring regulatory confidence and avoiding potential supply chain disruptions. 
#biotech #pharma @FDA $NVO $ALUR $SNY $SAN
#FDA #biotech #pharma #NVO #ALUR #SNY #SAN